Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients
IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as standard of care for all non-squamous non-small cell lung cancer (NSQ NSCLC) patients and is poised for future drug approvals. This advanced testing protocol aims to provide deeper insights into the molecular characteristics of NSQ NSCLC, facilitating more personalized and effective treatment strategies.
Approximately 50% of NSQ NSCLCs lack a targetable gene driver mutation, making MET protein expression an important additional personalized target. Caris is addressing these challenges by leveraging the power of MET IHC testing, which evaluates the expression of the MET protein in cancer cells. This protein is known to play a crucial role in cell proliferation, invasion, and survival, making it a vital biomarker for targeted therapies.
"To our knowledge, Caris is the only lab in the US that has historically and is currently offering the MET (SP44) RxDx assay for NSQ NSCLC," said Caris President David Spetzler, MS, PhD, MBA. "With MET IHC testing already in place, we are poised and ready to provide a detailed molecular profile to inform targeted therapies and future drug development approvals."
Key Highlights of MET IHC Testing:Comprehensive Molecular Profiling: Caris utilizes a multi-platform approach, including immunohistochemistry (IHC) and next-generation sequencing (NGS), to provide a detailed molecular profile of NSQ NSCLC tumors.
Identification of Actionable Targets: The MET IHC testing helps identify overexpression of the MET protein, which is associated with poor prognosis and can be targeted by specific therapies.
Enhanced Treatment Personalization: By understanding the molecular makeup of NSQ NSCLC tumors, oncologists can tailor treatment plans to the individual needs of patients, potentially improving outcomes and quality of life.
Caris remains committed to advancing cancer diagnostics and treatment through innovative technologies and rigorous scientific research. Deployment of MET IHC testing for NSQ NSCLC patients underscores this commitment and highlights Caris' dedication to improving patient care and outcomes.
Caris' comprehensive molecular profile testing includes MI Cancer Seek® and Caris Assure®. Caris received FDA approval in November of 2024 for MI Cancer Seek®, a tissue-based assay which is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. Caris Assure® is a powerful blood-based assay that uniquely identifies somatic tumor, incidental clonal hematopoiesis and incidental germline variants by sequencing both plasma and buffy coat through a WTS and WES-based assay.
About Caris Life SciencesCaris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multimodal database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides a differentiated platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. To learn more, please visit CarisLifeSciences.com.
Caris Life Sciences Media: Corporate CommunicationsCorpComm@CarisLS.com214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-provides-met-immunohistochemistry-testing-as-standard-of-care-for-non-squamous-non-small-cell-lung-cancer-patients-302451928.html
SOURCE Caris Life Sciences
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Dolbey Launches Ambient Clinical Intelligence Solution: Fusion Narrate ACI
CINCINNATI, June 11, 2025 /PRNewswire/ -- Dolbey has announced Fusion Narrate ACI™, an expansion of Fusion Narrate® powered by nVoq™, which offers ambient documentation for healthcare providers. Fusion Narrate ACI generates a transcript and draft report for each patient encounter. With Fusion Narrate ACI, patient encounters can be recorded securely through the HIPAA-compliant mobile Fusion Narrate Recorder smartphone app or directly through Fusion Narrate on a desktop workstation. After recording, Fusion Narrate ACI generates a draft report from the transcript of the patient encounter which can be shortened or expanded by section and inserted directly into the EHR. "I love Fusion Narrate ACI. It reduces click fatigue and takes me back to a more natural patient encounter," says Dr. Jamie Taweel, early adopter of Fusion Narrate ACI. "It also floats seamlessly between different EMR services, so you can use it at different offices or services. Now that I have Fusion Narrate ACI, I can't imagine going back." "Ambient clinical intelligence is a major milestone for documentation and speech recognition technology that is poised to completely shift how providers complete patient records and interact with their patients. Offering providers the opportunity to meet with their patients one-on-one and have a complete report and transcript prepared at the end of the encounter sounds like a dream, but it's now a reality," states John Dolbey, SVP and General Manager at Dolbey. "Fusion Narrate ACI is a truly cutting-edge and powerful solution that is made even more flexible by the customizability, automation capability, and application compatibility already existing within Fusion Narrate." Fusion Narrate ACI offers healthcare providers a new way to capture the details of a patient encounter with the familiar, intuitive Fusion Narrate interface. Dolbey's Fusion Narrate ACI is now available. Fusion Narrate ACI offers pay as you go pricing with no usage limits. Learn more at About DolbeyDolbey's award-winning healthcare suite of solutions enhances productivity while delivering better documentation, improving patient care. Since 1914, Dolbey has incorporated the latest technologies available to meet the demands of the healthcare community. Today, Dolbey's suite of products includes speech recognition (premise or cloud-based), CAPD, CDI, CAC, transcription, and dictation. To learn more about Dolbey's ambient solution and front-end speech recognition software for EHRs, LISs, RISs, and more, visit Media ContactBrian Gaysunas396504@ 624-2630 View original content to download multimedia: SOURCE Dolbey Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Liberty HealthShare Earns Charity Navigator Four-Star Rating
CANTON, Ohio, June 11, 2025 /PRNewswire/ -- Liberty HealthShare®, the nation's most-comprehensive healthcare sharing ministry, has earned a "Four-Star" rating by Charity Navigator, ranking it among the country's best non-profit organizations. This rating designates Liberty HealthShare, which is celebrating its 30th anniversary in 2025, as an official "Give with Confidence" charity, indicating that it is using its donations effectively based on Charity Navigator's criteria. Charity Navigator, the nation's largest and most influential non-profit evaluator, reviews more than 200,000 organizations on their accountability and finance, impact and results, culture and community, and leadership and adaptability. Liberty HealthShare's 90% score is its highest rating ever and is up from the previous 88% score. "We are delighted to provide Liberty HealthShare with third-party accreditation that validates their operational excellence," said Michael Thatcher, president and chief executive officer of Charity Navigator. "The Four-Star Rating is the highest possible rating an organization can achieve. We are eager to see the good work that Liberty HealthShare can accomplish in the years ahead." "Our Four-Star Charity Navigator rating is further validation that our members can trust our commitment to good governance and financial transparency, and also that we're using our donor's gifts effectively," said Dorsey Morrow, Liberty HealthShare chief executive officer. "We hope it will introduce our ministry to new supporters who can help us advance our vision to build a healthcare sharing community that exemplifies Jesus Christ and empowers like-minded people to manage their healthcare journey," he added. Liberty HealthShare has also earned a "GuideStar Gold Seal" from Candid, ranking it among the country's best non-profits for transparency and accountability. Established in 1995, Liberty HealthShare provides a cost-effective, faith-based alternative to health insurance. Members enjoy the freedom to choose their own providers while participating in a compassionate, Christian community. Transparency and stewardship are central, with programs tailored for families, seniors, and individuals. Liberty HealthShare offers six affordable medical cost sharing programs that are designed to fit the needs and budgets of individuals as well as different types and sizes of families. Suggested monthly share amounts for individuals range from $87-$369. Share amounts for families of four start at $319 per month. Most programs include access to both urgent care and mental wellness telehealth visits along with access to discounts for prescription drugs, dental care, vision care, and even LASIK surgery. Liberty Dental, the ministry's dental sharing program, features suggested monthly share amounts as low as $35 and allows members to see the dentist of their choice without any network restrictions. As Liberty HealthShare is not insurance, enrollment is available year-round with no requirement for special life events to qualify. For more information about its sharing programs visit or call (855) 585-4237. Earlier this year, Liberty HealthShare established the Sharing Hearts Fund for Pediatric Wellness, a charitable arm of the ministry that seeks to provide support to Stark County, Ohio families with medical needs related to pediatric wellness. Liberty HealthShare is a non-profit 501(c) (3) charitable Christian medical cost-sharing ministry focused on members helping each other in times of need. The faith-based program, which facilitates healthsharing for its members, is a caring community of health-conscious individuals and families who choose to support one another and agree to the Christian values of stewardship to make healthcare affordable for all. Liberty HealthShare is not an insurance company nor is it offered through an insurance company. Liberty HealthShare's Sharing Programs do not guarantee or promise that a member's medical bills will be paid or assigned to others for payment. Whether anyone chooses to pay a member's medical bills will be totally voluntary. As such, Liberty HealthShare's Sharing Programs should never be considered as a substitute for an insurance policy. Whether a member receives any payments for medical expenses and whether or not Liberty HealthShare continues to operate, the member is always liable for any unpaid bills. View original content to download multimedia: SOURCE Liberty HealthShare Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
DPHARM® Announces First Slate of Keynotes for 15th Annual Event
The Conference Forum announced the first keynotes of the DPHARM®: Disruptive Innovations to Modernize Clinical Research conference, including the former heads of Merck and FDA, for the 2025 meeting. NEW YORK, June 11, 2025 /PRNewswire/ -- The Conference Forum announced today the first set of keynotes for the 15th annual DPHARM: Disruptive Innovations to Modernize Clinical Research conference, taking place September 16-17, 2025, at the Loews Philadelphia Hotel in Philadelphia, PA. "The 2025 keynotes were highly recommended by R&D executives on innovating for patients during an unprecedented flurry of changes, as clinical trial protocols continue to add to the levels of patient and site burden," said Tracey Kimball, DPHARM Conference Director. "We are at a real moment of inflection and change in our industry. This year's lineup represents an incredible list of keynote speakers that have seen it all over the years and I'm excited to hear their expert thoughts on what happens next and how we can innovate our way through the challenges in front of us," said Sean Lynch, Clinical Innovation Head, Innovative Trial Operations, Novartis and 2025 DPHARM advisor. The 2025 keynotes include: Kenneth C. Frazier, JD, retired Chairman and CEO of Merck & Co, Inc, and Chairman, Health Assurance Initiatives of General Catalyst, speaks on leading with integrity through times of change and fostering a culture that supports innovation. Scott Gottlieb, MD, 23rd Commissioner of the US Food and Drug Administration, speaks on the future of clinical research and the current and potential impact of the geopolitical landscape on R&D. Victoria Gray, Patient Advocate, speaks on her experience as the first CRISPR gene therapy recipient for sickle cell disease and the profound impact a clinical trial had on her life. Kenneth Getz, MBA, Director and Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine, speaks on addressing protocol complexity to lessen the burden of participation for sites and patients. "Our industry has always been shaped by waves of change – each one challenging, each one filled with possibility. I'm inspired to hear Ken Frazier share how we can lead with purpose and integrity, transforming the current moments of disruption into a catalyst for innovation and sustainable impact," said Dennis Salotti, Executive Director & Head of Clinical Outsourcing & Innovation, Jazz Pharmaceuticals and 2025 DPHARM advisor. In addition to the keynotes, DPHARM 2025 has over 200 speakers. The DPHARM agenda is carefully curated with the guidance of over 75 advisors representing pharmaceutical senior clinical operation executives, patient advocacy, clinical sites, innovative tech and service companies, academia and regulatory authorities. DPHARM will be preceded by the Partnerships with Sites summit and the 10th annual CRAACO®: Clinical Research as a Care Option conference, September 15, 2025. To learn more, visit For the full DPHARM agenda, visit About DPHARM:DPHARM®: Disruptive Innovations to Modernize Clinical Research offers an unparalleled opportunity to hear senior clinical operations executives and innovative thought leaders report on innovations that are modernizing clinical trials and reducing patient burden. The concept of DPHARM was founded by Pfizer and Johnson & Johnson, who continue to play a key role on the steering committee to deliver a highly relevant and engaging program. DPHARM takes place September 16-17 at the Loews Philadelphia Hotel in Philadelphia, PA where its inaugural meeting took place. About The Conference Forum: The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. The company also publishes digital editorial across six categories, and produces PharmaTalkRadio, virtual events, and webinars. View original content: SOURCE DPHARM Sign in to access your portfolio
